Phase 1 Study of Oral MG001

NCT07204171 | Not Yet Recruiting Phase 1 DMC FDA Drug

• 2 other identifiers: NIDA-MG001-Ph1a-00175N95023D20019
• Study Type: interventional
• Target: 32
• Locations: 1 country
• Sites: 1

Brief Summary

This research study is the first time the new medication MG001 is being tested in people. MG001 is a formulation of mitragynine, a compound that comes from a plant called Mitragyna speciosa (sometimes known as kratom), which some people use on their own to help manage symptoms of opioid withdrawal. The purpose of this study is to understand how safe MG001 is, how well it is tolerated, and how the body processes it. About 32 healthy adult volunteers, both men and women, will take part. Before joining, participants will undergo screening tests up to four weeks in advance to make sure they are eligible and healthy enough. On the day before dosing, participants will be admitted to the clinic for final health checks, and those who qualify will be randomly assigned-by chance, like flipping a coin-to receive either a single dose of MG001 or a placebo (an inactive substance). Neither the participants nor the staff giving the medicine will know which one is given. The study drug will be administered after at least 10 hours of fasting, and participants will then remain in the research clinic under close medical observation for three nights, until Day 4. During this time, doctors and nurses will monitor participants' health, look for any side effects, and collect blood samples to see how MG001 moves through the body. A follow-up clinic visit on Day 7 will provide one last check-in and blood test. This design helps researchers gather important first information on the safety and tolerability of MG001, while protecting the health and well-being of participants.

Conditions

Safety and Tolerability in Healthy Subjects

Keywords

mitragynine; kratom; opioid use disorder; opioid withdrawal

Outcome Measures

Primary Outcomes (1)

• Incidence of Treatment-Emergent Adverse Events in Healthy Adult Participants

  The incidence of treatment-emergent adverse events will be measured using a combination of data collection methods, including tracking adverse events and assessing their onset or worsening relative to the initiation of treatment. The most recent version of the Medical Dictionary for Regulatory Activities (MedDRA) preferred terms will be used to classify adverse events, including their relationship to the treatment and maximum severity. Events will be identified either through subject self-report or clinically significant abnormal findings on: (i) Physical examination (ii) Vital signs assessments (heart rate (BPM), blood pressure (mmHg), respiration rate (BPM), hemoglobin saturation (%) and temperature (F)) (iii) ECG assessment (QTcF) as determined by the Investigator/consulting board-certified cardiologist (iv) pupil constriction (mm) (v) sedation as measured by VAS (score) and MOAA/S (score (vi) Clinical Laboratory Assessments

  4 days in clinic, follow-up on day 7

Secondary Outcomes (4)

• Cmax

  144 hours

• AUC

  144 hours

• Tmax

  144 hours

• half-life (t1/2)

  144 hours

Study Arms (5)

25 mg dose

EXPERIMENTAL

oral administration in fasted state

Drug: mitragynine

50 mg dose

EXPERIMENTAL

oral administration in fasted state

Drug: mitragynine

75 mg dose

EXPERIMENTAL

oral administration in fasted state

Drug: mitragynine

100 mg dose

EXPERIMENTAL

oral administration in fasted state

Drug: mitragynine

Placebo

PLACEBO COMPARATOR

oral administration in fasted state

Drug: Placebo

Interventions

mitragynine DRUG

Mu opioid receptor partial agonist

100 mg dose; 25 mg dose; 50 mg dose; 75 mg dose

Placebo DRUG

Each of the four dose groups of n=8 participants will be assigned to active drug or placebo in the ration 6:2.

Placebo

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Is a healthy male or female volunteer between 18 and 65 years of age, inclusive, at the time of consent.
• Has a body mass index (BMI) within the range of 18.0 to 32.0 kg/m2 and a minimum weight of at least 50.0 kg at screening.
• Has a recent history of oral opioid use , defined as using prescription or recreational oral opioids at least once during the 30-day period preceding screening.
• Is able to speak English sufficiently to understand the study procedures and provide written informed consent to participate in the study.
• Has no clinically significant concurrent medical conditions determined by medical history, physical examination, clinical laboratory test , vital signs, and 12-lead ECG.
• A female study participant must be of non-childbearing potential - should be surgically sterile (i.e., has undergone complete hysterectomy, bilateral oophorectomy, bilateral salpingectomy or tubal ligation/occlusion) or in a menopausal state (at least 1 year without menses), as confirmed by follicle stimulating hormone (FSH) levels (≥40 mIU/mL).
• If a male study participant that engages in sexual activity that has the risk of pregnancy, must agree to use a double barrier method (e.g., condom and spermicide) and agree to not donate sperm during the study and for at least 90 days after the last dose of the study medication.
• Is able and willing to comply with protocol requirements and the rules and regulations of the study site and is likely to complete all the study treatments.

You may not qualify if:

• Has any clinically significant finding within one year of Screening on medical history, physical examination, complete neurological examination, clinical laboratory test, vital signs (including hemoglobin saturation assessed by pulse oximetry, RR, HR, BP, oral body temperature ), or ECGs that contraindicate participation in the study. This includes but is not limited to history of or current cardiac, hepatic, renal, neurologic, gastrointestinal (GI) , pulmonary, endocrinologic, hematologic, or immunologic disease or history of malignancy.
• Has clinically significant psychiatric symptoms and/or psychiatric comorbidities (schizophrenia, bipolar disorders, mania, unipolar depression, disruptive behaviors, etc.), or a history of such within one year of screening. Psychiatric assessment will be conducted by a Qualified Mental Health Professional using the Mini-International Neuropsychiatric Interview (MINI).
• Has a history of suicide attempts or evidence of suicidal ideation based on the Columbia-Suicide Severity Rating Scale (C-SSRS):
• Any lifetime history of serious or recurrent suicidal behavior.
• Previous history of suicidal behaviors in the past 10 years.
• Suicidal ideation with or without a plan (active or passive, respectively) in the past year.
• Has a history of epilepsy, seizure disorder, or head trauma with neurological sequelae (e.g., loss of consciousness that required hospitalization); current anorexia nervosa or bulimia; or any other conditions that increase seizure risk in the opinion of the study clinician.
• Has a history of thyroid and/or parathyroid disease or abnormal T4 or PTH levels.
• Has evidence of second or third degree heart block, atrial fibrillation, atrial flutter, prolongation of the QTc, or any other finding on the screening ECG that, in the opinion of the study medical clinician, would preclude safe participation in the study.
• Has any clinically significant abnormal laboratory values
• Has taken kratom or any investigational drug in another study within 30 days of study consent.
• Requires treatment with opioid-containing medications (e.g., opioid analgesics) during the study period.
• Has used opioids intravenously or on 3 or more consecutive days during the 30 day period preceding screening.
• Has a sitting systolic blood pressure (SBP) \>140 mmHg, diastolic BP (DBP) \>90 mmHg or HR \<50 or \>100 beats per minute (BPM) at screening and clinic intake.
• Has orthostatic hypotension, defined as a 20 mmHg reduction in SBP and 10 mmHg in DBP.

Sponsors & Collaborators

• National Institute on Drug Abuse (NIDA): lead
• Altasciences Clinical Kansas, Inc.: collaborator
• Technical Resources International, Inc. (TRI): collaborator

Study Sites (1)

Altasciences Clinical Kansas

Overland Park, Kansas, 66212, United States

Location

MeSH Terms

Conditions

Opioid-Related Disorders

Interventions

mitragynine

Condition Hierarchy (Ancestors)

Narcotic-Related Disorders; Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders

Study Officials

• Julia Solarczyk Donnelly, MS, RAC

  National Institute on Drug Abuse, NIH

  STUDY DIRECTOR

Central Study Contacts

Debra Kelsh, MD

CONTACT

913-696-1601; DKelsh@altasciences.com

Sage Hannan, BA

CONTACT

913-696-1601; shannan@altasciences.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: NIH
• Responsible Party: SPONSOR

Model Details: This is first-in-human (FIH), randomized, double-blind, placebo-controlled, single ascending dose (SAD), phase I study in healthy participants. Four single ascending dose levels under fasting conditions are proposed.

Study Record Dates

• First Submitted: September 24, 2025
• First Posted: October 2, 2025
• Study Start: February 1, 2026
• Primary Completion (Estimated): August 1, 2026
• Study Completion (Estimated): August 1, 2026
• Last Updated: October 2, 2025

Record last verified: 2025-09

Locations

US (1)